Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 2:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 11,977 matching trials from the live ClinicalTrials.gov search.
Conditions
Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions
sunitinib malate, immunohistochemistry staining method, TdT-mediated dUTP nick end labeling assay, light microscopy, laboratory biomarker analysis
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Cleveland, Ohio
Conditions
Lung Cancer, Adenocarcinoma
Interventions
Phase I - GM.CD40L.CCL21 Vaccinations, Phase II - GM.CD40L cells Vaccinations, Phase II - GM.CD40L.CCL21 Vaccinations
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Metastatic Extrahepatic Bile Duct Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Stage D Adult Primary Liver Cancer (BCLC), Unspecified Adult Solid Tumor, Protocol Specific
Interventions
PET scan, CT Scan, hepatic artery embolization
Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
ispinesib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Non Small Cell Lung Cancer
Interventions
biospecimen collection
Other
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 3 more
Conditions
Hepatocellular Carcinoma
Interventions
PR104 550 mg/m^2 + sorafenib, PR104 770 mg/m^2 + sorafenib
Drug
Lead sponsor
Proacta, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Tucson, Arizona • La Jolla, California • Orange, California + 6 more
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
390
States / cities
Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 290 more
Conditions
Lung Cancer
Interventions
questionnaire administration, computed tomography, radiation therapy treatment planning/simulation
Other · Procedure · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Breast Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Larynx, Lip, Oral Cancer, Digestive Organs--Diseases
Interventions
Durvalumab, Intensity Modulated Radiotherapy Treatments
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina • Charleston, South Carolina
Conditions
Ovarian Cancer
Interventions
Bevacizumab, Carboplatin, Docetaxel, Gemcitabine, Melphalan, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Choledocholithiasis, Bile Duct Diseases, Bile Duct Carcinoma
Interventions
"Air" contrast cholangiography using carbon dioxide gas
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Akt Inhibitor MK2206, Therapeutic Conventional Surgery, Pharmacological Study, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Conditions
HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions
Lumason, Sonazoid
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Eribulin Mesylate, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
12
States / cities
Anchorage, Alaska • Tucson, Arizona • Bozeman, Montana + 7 more
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Bevacizumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
34
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
Terminated Phase 1Phase 2 Interventional Results available

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

NCT03901573
Conditions
Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Interventions
NT-I7, atezolizumab
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Conditions
Ovarian Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Cabozantinib, Pembrolizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
5
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 2 more
Conditions
Bladder Cancer, Urothelial Carcinoma
Interventions
18F-fluciclovine, PET/CT
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Not listed
Lead sponsor
Applied Spectral Imaging Ltd.
Industry
Eligibility
20 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Temple, Texas
Conditions
Esophageal Cancer
Interventions
carboplatin, Pemetrexed, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
90
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 54 more
Conditions
Unresectable Hepatocellular Carcinoma (HCC)
Interventions
NMS-01940153E
Drug
Lead sponsor
Nerviano Medical Sciences
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Orange, California • St Louis, Missouri